Hoddesdon, 3rd September 2010 —MSD* announced today that the European Commission has approved the Marketing Authorisation Application (MAA) for'Sycrest'® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.